Enabling genomic surveillance from 30 years of linked English sentinel network data: The Wellcome Quinquagenarian (QQG) Biomedical Resource
Authors:
- Simon de LusignanSLSimon de Lusignan
- Praveen SebastianPillaiPSPraveen SebastianPillai
- Omid ParviziOPOmid Parvizi
- Cecilia OkusiCOCecilia Okusi
- Mark JoyMJMark Joy
- Shuma BanikSBShuma Banik
- Fatima BatoolFBFatima Batool
- Katja HoschlerKHKatja Hoschler
- Beatrix KeleBKBeatrix Kele
- Angie LackenbyALAngie Lackenby
- Joanna EllisJEJoanna Ellis
- Richard PebodyRPRichard Pebody
Open Access
- 4 August 2025
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 10, 411
Abstract
Background The World Health Organisation recommends integrating viral genome sequences and sentinel surveillance data. We report progress in linking clinical, virology, and sequence data to enable genomic surveillance of influenza, respiratory syncytial virus (RSV), and severe-acute-respiratory-syndrome coronavirus-2 (SARS-CoV-2). Methods We linked individual-level clinical data from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) sentinel network to virology results from the UK Health Security Agency (UKHSA) reference virology laboratory. We identify where publicly accessible repositories, the Global Initiative on Sharing All Influenza Data (GISAID), or others hold viral genome sequence data from test-positive cases. Our metadata also identifies test-negative controls contemporaneous to test-positive cases. We summarise the scope of data availability in the Wellcome Quinquagenarian (QQG) biomedical resource. Results We report respiratory virus sampling for influenza, RSV, and SARS-CoV-2 between 1992 and 2023. Samples were collected from a nationally representative subset of RSC general practices participating in the virological surveillance programme. QQG contains 13,665 positive influenza samples, 3,791 positive RSV samples, and 5,068 positive SARS-CoV2 samples. There were 2,819 sequenced influenza genomes, of which 97.1% were linked to clinical records, 1,251 sequenced RSV genomes of which 96.8 were linked to clinical records, and 2,486 sequenced SARS-CoV-2 genomes of which 98.9% were linked to clinical records. Conclusion We have described the scale of QQG, created to enable genomic surveillance linked to clinical metadata to facilitate research on the impact of different viral variants on clinical outcomes, vaccine effectiveness, and therapeutic strategies.Keywords
Funding Information
- Wellcome Trust (212763)
This publication has 57 references indexed in Scilit:
- Lessons from the English primary care sentinel network's response to the COVID-19 pandemicThe Lancet Infectious Diseases, 2023
- An appeal for strengthening genomic pathogen surveillance to improve pandemic preparedness and infection prevention: the German perspectiveInfection, 2023
- Toward a global virus genomic surveillance networkCell Host & Microbe, 2023
- Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groupsJournal of Infection, 2022
- International federation of genomic medicine databases using GA4GH standardsCell Genomics, 2021
- Genomic-informed pathogen surveillance in Africa: opportunities and challengesThe Lancet Infectious Diseases, 2021
- Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance studyThe Lancet Infectious Diseases, 2020
- Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020eClinicalMedicine, 2020
- End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19Vaccine, 2020
- Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational studyThe Lancet, 2001